Unfractionated heparin drug is an anticoagulant drug. It is a high molecular weight heparin drug ranging from 3,000 Da to 30,000 Da. The unfractionated heparin drug is a heterogeneous mixture of linear polysaccharide chains with variable biological activity and molecular weight, and a pentasaccharide that has minimal active fragment. Unfractionated heparin is the most primitive form of heparin and has major applications in kidney dialysis and heart, and lung oxygenation that includes the treatment and prevention of pulmonary embolism, deep vein thrombosis, post-operative thrombosis, certain types of coronary artery syndrome, particularly unstable angina, in thrombotic stroke, and hemodialysis.
Unfractionated heparin binds reversibly with anti-thrombin III (ATIII). This enhances the rate at which ATIII inactivates coagulation enzymes such as thrombin factor Xa and factor IIa. Unfractionated heparin is primarily utilized in hospitals for the prevention and treatment of thrombosis. In 2008, numerous consignments of heparin imported to the U.S. from China were contaminated with oversulfated chondroitin sulfate. This led to the establishment of stringent production and purification guidelines worldwide. According to the University of Wisconsin Hospitals and Clinics Authority, unfractionated heparin is a better option as compared to low molecular weight heparin as the former is used intravenously for the treatment of anticoagulation. The adjustment of infusion rate and monitoring is required for the immediate onset of the intravenous unfractionated heparin.
Get PDF Brochure for more Professional & Technical industry insights: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32198
Unfractionated heparin is eliminated through the liver. It gets eliminated faster due to its high molecular weight, and it is highly preferred in dialysis. This is a driving factor for the growth of the global unfractionated heparin drug market. Several studies have confirmed that unfractionated heparin has more specificity than low molecular weight heparin, and its effect can be reversed by using protamine sulfate. This advantage over low molecular weight heparin has led unfractionated heparin to sustain in the market. According to the World Health Organization (WHO), there is a high risk for the development of venous thromboembolism which is caused due to prolonged traveling in passengers via automobile, bus, train, or airplane, for more than four hours. This is one of the driving factors of the market growth. However, increasing use of anticoagulants in dialysis as an alternative has decreased the usage of unfractionated heparin, which is likely to restraint the growth of the market for unfractionated heparin drug during the forecast period.
The global unfractionated heparin drug market has been categorized based on type of packaging, dosing type of body weight, type of strength, end-user, and region. In terms of type of packaging, the market is divided into ampoules, multi-dose vials, single-dose vials, and prefilled/preloaded syringes. On the basis of dosing type of body weight, the market is segmented into morbidly obese patients, obese patients, and non-obese patients. In terms of type of strength, the market is segmented into 2,000, 5,000, 10,000, 20,000, and above 20,000 billion units. In terms of end-user, the market is categorized into hospitals, nursing homes and private clinics, assisted living facilities (ALFs) & long term care institutions, and home health care.
Geographically, the global unfractionated heparin drug market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold a large share of the global market during the forecast period owing to technological developments. The market in Asia Pacific is anticipated to grow during the forecast period owing to increasing government initiatives and growing awareness.
Key players operating in the global unfractionated heparin drug market include Dr. Reddy’s Laboratories Ltd., Fresenius Kabi AG, LEO Pharma A/S, Pfizer, Inc., and Sanofi S.A.